依贝沙坦联合羟苯磺酸钙治疗2型糖尿病肾病的疗效分析

Clinical analysis of irbesartan combined with calcium dobesilate in treatment of diabetic nephropathy

目的观察羟苯磺酸钙与依贝沙坦单独及联合应用对2型糖尿病肾病患者的临床疗效,以及长期应用的有效性与安全性。方法以2008年5月～2012年10月收治的120例2型糖尿病肾病患者伴高血压为研究对象,分为两组,每组60例,依贝沙坦组给予依贝沙坦0.15g,联合用药组给予羟苯磺酸钙500mg和依贝沙坦0.15g。结果两药单独应用和联合应用均可明显降低糖尿病肾病高血压(P<0.05),降低24h尿白蛋白排出(P<0.05),联合治疗降压作用和改善肾功能损伤作用明显优于单独治疗(P<0.05)。结论羟苯磺酸钙、依贝沙坦治疗2型糖尿病肾病高血压均有较好的降压作用和改善肾功能损害,两药联合应用具有协同作用,值得临床推广应用。

Objective To observe the effect of irbesartan combined with calcium dobesilate in treatment of diabetic nephropathy among type 2 diabetic patients. Methods 120 patients of type 2 diabetic patients with hypertension were divided into irbesartan group and combination group, 60 cases in each group. In irbesartan group, patients were only treated with irbesartan（0.15 g）, and the combination group patients were treated with irbesartan （0.15 g） and calcium dobesilate （ 500 mg ）. Results In all groups, the blood pressure level and 24 h urine albumin decreased significantly when compared with prior treatment （P 〈 0.05）. The combination of irbesartan and calcium dobesilate leaded to a more significant reduction of blood pressure level and 24 h urine albumin （P 〈 0.05）. Conclusion Irbesartan and calcium dobesilate combined application in type 2 diabetic patients with diabetic nephropathy was more efficient in controlling blood pressure and improving renal injury. Therefore, the combination treatment is worthy of application in clinic.